ACCESSA LAUNCHES OSTEOACCES, AN INNOVATIVE THERAPEUTIC ADHERENCE PROGRAM FOR PATIENTS WITH OSTEOPOROSIS Français
Osteoacces marks a significant step forward in supporting patients with osteoporosis who are being treated with denosumab. The program provides pharmacies with tools and additional resources to better support patients throughout their treatment. This innovative initiative aims to improve therapeutic adherence, a key factor in treatment success. By placing patients at the heart of our approach, we believe Osteoacces can enhance their experience at every stage of their care journey.
Accessa leverages its unique technology platform, Curo TM, to guide and support community pharmacies throughout the treatment process. This results in optimal medication use and, consequently, better health outcomes. "The WHO reports that 50% of patients treated for a chronic disease do not adhere to their prescribed medication 1. In the case of patients with osteoporosis, adherence to treatment is a determining factor in therapeutic success, as non-adherence has been associated with an increased risk of fractures 2. With Osteoacces, we're offering a concrete, inclusive, and accessible solution for patients undergoing treatment for osteoporosis," says Jean Bourcier, President of Accessa.
Sandoz Canada is the first manufacturer to join the program with Jubbonti ®, the first and only biosimilar of denosumab (reference product Prolia ®) approved by Health Canada.
"Sandoz is proud to be a business partner to pharmacies across Quebec, supporting pharmacists in the care and management of their patients."
Osteoacces is open to all manufacturers commercializing a biosimilar for the treatment of osteoporosis who wish to partner with Accessa to promote patient adherence to treatment.
A new range of programs focused on patients' medical conditions
This launch is part of a broader vision led by the Adhaesio ™ program line, which will include several therapeutic adherence programs, each dedicated to a specific molecule or health condition. Each Adhaesio™ program will promote medication adherence by supporting pharmacist-led care, regardless of the prescribed brand. This approach enables both patients and healthcare professionals to focus on achieving successful treatment outcomes.
About Accessa
Accessa is the manager of a new generation of patient support programs (PSPs), fully owned by Quebec's community pharmacists through the Association québécoise des pharmaciens propriétaires (AQPP). Our mission is to provide our partners with innovative, compliant, and scalable solutions that enable patients to access comprehensive management of their medication therapy including complex treatments through the pharmacist of their choice.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
7 hours ago
- Cision Canada
Pendopharm® signs an exclusive distribution agreement with Neuraxpharm for PrBuccolam® in Canada and announces its approval by Health Canada Français
MONTREAL, Aug. 4, 2025 /CNW/ - Pendopharm, a division of Pharmascience Inc., is pleased to announce that it has entered into an exclusive distribution agreement with Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, headquartered in Düsseldorf, Germany. Under the terms of the agreement, Pendopharm ® will be responsible for the commercialization of Buccolam ® (Midazolam Hydrochloride Oromucosal Solution) in Canada. Buccolam ® is indicated for the treatment of prolonged, acute, convulsive seizures in children. Pendopharm ® is pleased to announce that Health Canada has approved Buccolam ®. About Epilepsy Epilepsy is a chronic neurological disorder characterized by recurrent seizures of various types and severity. These seizures result from abnormal electrical activity in the brain and can be triggered by a range of factors, including structural abnormalities, brain inflammation, physical injury, trauma, infection, or unknown causes. It is estimated that the underlying cause of epilepsy remains undetermined in up to 50% of patients diagnosed with epilepsy. 1 Nearly 1 out of 100 Canadians live with epilepsy, and approximately 13% of them are children and youth. 1 Despite treatment with anti-seizure medications, some patients may experience prolonged acute convulsive seizures which require immediate intervention. Early treatment of acute seizures is critical to prevent escalation and improve patient outcomes. 2,3 Benzodiazepines, are considered first-line therapy for managing prolonged seizures. 4 Buccolam ® is an oromucosal solution of midazolam (a benzodiazepine) supplied in a ready-to-use, pre-filled syringes for buccal (absorbed in the mouth) administration. 5 "Prolonged convulsive seizures in pediatric patients can have significant short- and long-term impacts", said Dr. Aris Hadjinicolaou, Pediatric Neurologist at CHU Sainte-Justine. "Having access to a ready-to-use, on-label medication could facilitate timely intervention during seizures and may decrease the need for emergency medical services". " This partnership represents Pendopharm's commitment to bringing medicines that address unmet medical needs to Canadian patients," said Jad Isber, Vice President & General Manager of Pendopharm ®. "We look forward to working with Canadian neurologists and pediatricians to make Buccolam available to all patients who may benefit from it." Dr. Maximilian von Wülfing, Chief Operating Officer of Neuraxpharm, said: "Through its network of strategic partnerships around the world, Neuraxpharm is committed to expanding access to market-leading medicines. Our collaboration with Pendopharm further strengthens our position as a global CNS specialist enabling us to deliver an epilepsy treatment designed to reduce hospitalizations and provide support to patients and their caregivers." About Pendopharm ® Pendopharm, specialty division of Pharmascience Inc., is a leading Canadian specialty pharmaceutical company providing patients with innovative medicines that address unmet medical needs. Its areas of focus are gastroenterology, sports medicine & orthopedics, neurology and cardiology. Pendopharm ® has extensive experience and knowledge to successfully manage its growing product portfolio. For more information, please visit For media inquiries, please contact [email protected]. © 2025 Pendopharm, division of Pharmascience Inc. All rights reserved. About Pharmascience Inc. Pharmascience Inc. is one of the largest pharmaceutical manufacturers in Canada and is headquartered in Montreal, Canada. Pharmascience delivers high-quality medicines to over 50 countries worldwide. Pharmascience Inc.'s global presence and agile business development model provide healthcare communities around the world with the high-quality Canadian medicines to respond to patients' needs. About the Neuraxpharm Group Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders. It has a unique understanding of the CNS market built over 40 years. Neuraxpharm is constantly innovating, with new products and solutions to address unmet patient needs and is expanding its portfolio through its pipeline, partnerships and acquisitions. The company has c.1,000 employees and develops and commercialises CNS products through a direct presence in more than 20 countries in Europe, two in Latin America, one in the Middle East, one in Australia, and globally via partners in more than 50 countries. Neuraxpharm is backed by funds advised by Permira. Neuraxpharm manufactures many of its pharmaceutical products at Neuraxpharm Pharmaceuticals (formerly Laboratorios Lesvi) in Spain. For more information, please visit .
Cision Canada
8 hours ago
- Cision Canada
Gates Foundation Announces Catalytic Funding to Spark New Era of Women-Centered Research and Innovation
Investments Through 2030 to Catalyze Innovation in Maternal, Menstrual, Gynecological, and Sexual Health for Women Globally SEATTLE, Aug. 4, 2025 /CNW/ -- The Gates Foundation today announced a $2.5 billion commitment through 2030 to accelerate research and development (R&D) focused exclusively on women's health. It will support the advancement of more than 40 innovations in five critical, chronically underfunded areas—particularly those affecting women in low- and middle-income countries. "For too long, women have suffered from health conditions that are misunderstood, misdiagnosed, or ignored," said Dr. Anita Zaidi, president of the Gates Foundation's Gender Equality Division. "We want this investment to spark a new era of women-centered innovation—one where women's lives, bodies, and voices are prioritized in health R&D." Women's health R&D remains chronically underfunded. Areas such as gynecological and menstrual health, obstetric care, contraceptive innovation, sexually transmitted infections (STIs) solutions (including HIV PrEP for women), and maternal health and nutrition receive limited investment. According to a 2021 analysis, led by McKinsey & Company, just 1% of healthcare research and innovation is invested in female-specific conditions beyond oncology. Critical issues like preeclampsia, gestational diabetes, heavy menstrual bleeding, endometriosis, and menopause, which together affect hundreds of million women, remain deeply under-researched. "Investing in women's health has a lasting impact across generations. It leads to healthier families, stronger economies, and a more just world," said Bill Gates, chair of the Gates Foundation. "Yet women's health continues to be ignored, underfunded, and sidelined. Too many women still die from preventable causes or live in poor health. That must change. But we can't do it alone." To close persistent gaps in funding and research, the foundation is urging governments, philanthropists, investors, and the private sector to co-invest in women's health innovations, help shape product development, and ensure access to treatments for the women and girls who need them most. "This is the largest investment we've ever made in women's health research and development, but it still falls far short of what is needed in a neglected and underfunded area of huge human need and opportunity," said Zaidi. "Women's health is not just a philanthropic cause—it's an investable opportunity with immense potential for scientific breakthroughs that could help millions of women. What's needed is the will to pursue and follow through." The foundation's investment will advance innovation across five high-impact areas of a woman's lifespan: Obstetric care and maternal immunization: Making pregnancy and delivery safer Maternal health and nutrition: Supporting healthier pregnancies and newborns Gynecological and menstrual health: Advancing tools and research to better diagnose, treat, and improve gynecological health and reduce infection risk Contraceptive innovation: Offering more accessible, acceptable, and effective options Sexually transmitted infections (STIs): Improving diagnosis and treatment to reduce disproportionate burdens on women Areas of breakthrough potential include research into the vaginal microbiome, first-in-class therapeutics for preeclampsia, and non-hormonal contraception. Included in the commitment are investments that will support data generation and advocacy to help ensure product uptake and impact upon approval. The five priority areas were selected based on a combination of data and evidence about where innovation can save and improve the most lives, direct insights from women in low- and middle-income countries about their needs and preferences, and the persistently high rates of misdiagnosis caused by gaps in medical knowledge and training. They also reflect the unique challenges faced in low-resource settings, making these areas especially ripe for broader public and private investment to drive meaningful, scalable impact. "We see the consequences of underinvestment in women's health innovation every day when women suffer needlessly, and sometimes lose their lives, because of the gaps in how we understand and treat conditions that uniquely affect them," said Dr. Bosede Afolabi, professor of obstetrics and gynecology at the College of Medicine, University of Lagos. "This commitment brings much-needed attention to the health challenges women face in places where resources are most limited and the burden is highest. It reflects a recognition that women's lives—and the innovations that support them—must be prioritized everywhere." By addressing long-standing gaps in women's health, the investment aims to unlock broader social and economic gains. Research shows that every $1 invested in women's health yields $3 in economic growth, and closing the gender health gap could boost the global economy by $1 trillion per year by 2040. This work supports the foundation's long-term goals through 2045: helping to end preventable deaths of moms and babies; ensuring the next generation grows up without having to suffer from deadly infectious diseases; and lifting millions of people out of poverty, putting them on a path to prosperity. It builds on a 25-year legacy of advancing maternal and child health and supporting women's empowerment globally. The R&D commitment complements the foundation's work supporting the scale-up and delivery of women's health commodities, vaccines such as the HPV vaccine, and child health. About the Gates Foundation Guided by the belief that every life has equal value, the Gates Foundation works to help all people lead healthy, productive lives. In developing countries, we work with partners to create impactful solutions so that people can take charge of their futures and achieve their full potential. In the United States, we aim to ensure that everyone—especially those with the fewest resources—has access to the opportunities needed to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Mark Suzman, under the direction of Bill Gates and our governing board.
Cision Canada
8 hours ago
- Cision Canada
Pulsecare Medical Announces NMPA Approval of NxPFA™, the World's First Nanosecond PFA System, Ushering in the PFA 3.0 Era
SHENZHEN, China, Aug. 4, 2025 /CNW/ -- Pulsecare Medical, a pioneer in cardiovascular intervention technologies, announced that its innovative NxPFA™ nanosecond pulsed field ablation (ns-PFA) systemhas received marketing approval from China's National Medical Products Administration (NMPA). As the world's first third-generation ns-PFA system utilizing high-voltage nanosecond pulses for pulmonary vein isolation (PVI) in atrial fibrillation (AF) treatment, this breakthrough marks the dawn of the PFA 3.0 era and represents the innovative capabilities of Pulsecare Medical in cardiovascular multimodal therapy. The World's First Commercially Approved Nanosecond PFA PFA has revolutionized AF treatment through its tissue selectivity, safety, and procedural efficiency. Yet, early-generation systems using microsecond pulses face key challenges—excessive muscle stimulation, reliance on general anesthesia, and risks like hemolysis and gas embolism—that limit broad adoption. As the world's first and only commercially available nanosecond PFA system, NxPFA™ represents the "Next of PFA" generation. It combines the MaviPulse™ high repetition frequency ns-PFA console with the InteShot™ basket-shaped catheter to deliver irreversible electroporation of cardiomyocytes via high-voltage nanosecond pulses, effectively overcoming key limitations of microsecond PFA (μs-PFA) technologies: Significantly reduces neuromuscular stimulation, enabling procedures under conscious sedation, improving patient comfort and lowering anesthesia risks; Combines nanosecond pulses with a basket-shaped catheter to ensure optimal electrode-tissue contact and high success rates, while shortening procedural time; Substantially lowers intravascular gas formation, lowering the risk of stroke or systemic embolism; Minimizes erythrocytic damage and post-procedural bilirubin elevation, reducing potential kidney injury. NxPFA™ Demonstrates Outstanding Efficacy and Safety The NxPFA ™ system has been clinically validated through the SCENA-AF multicenter registration trial, which enrolled 166 patients with paroxysmal atrial fibrillation. The data has been acknowledged by NMPA and will soon be published in an academic journal. Key outcomes include: 100% acute pulmonary vein isolation success rate 88.27% one-year treatment success rate (PPS) No device-related serious adverse events reported Over 92.8% of procedures completed under conscious sedation, with excellent intraoperative tolerance. These results confirm NxPFA ™ 's strong performance in efficacy, safety, efficiency, and patient comfort. It remains the only PFA system globally to achieve one-shot PVI under conscious sedation with high success, marking the debut of the third-generation nanosecond PFA era. "NxPFA ™ 's approval is not only a major milestone for Pulsecare Medical but also a transformative breakthrough for cardiac electrophysiology. With NxPFA ™, we address critical clinical challenges and look forward to collaborating with global EP experts to shape the future of arrhythmia treatment—delivering smarter tools to physicians and safer, more effective, more comfortable therapies to patients," said Dr. Javen Tan, CEO of Pulsecare Medical. Founded in July 2021 and headquartered in Shenzhen, Pulsecare Medical is dedicated to the innovation and development of cardiovascular multimodal therapeutic devices. Backed by a rare cross-disciplinary team combining clinical and engineering expertise, the company is building a next-generation energy platform for interventional therapies. Pulsecare offers total solutions for cardiac electrophysiology and hypertension interventional therapy, aiming to lead in minimally and non-invasive treatments.
